Myomo (MYO) Tops Q4 EPS by 8c

Myomo (NYSE: MYO) reported Q4 EPS of ($0.25), $0.08 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $547 thousand versus the consensus estimate of $350 thousand.

Paul R.Gudonis, Chairman & CEO of Myomo, stated: “2017 was an important year for Myomo as we continued to build our operational and commercial capabilities for the MyoPro product line. During the year, we completed our IPO and follow-on offering to raise growth capital to fund our transition from our controlled launch phase to now scaling up operations. In 2018, we look forward to continued execution of our business plan, and our mission to restore functionality to the many individuals with upper limb paralysis. We continue our efforts to bring awareness to veterans and the broader clinical and patient communities, as we target this large unmet need.”

For earnings history and earnings-related data on Myomo (MYO) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Byline Bancorp (BY) Tops Q1 EPS by 6c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance